Empower the Potential of Trastuzumab Deruxtecan with Novel Combinations

Clin Cancer Res. 2023 Nov 1;29(21):4317-4319. doi: 10.1158/1078-0432.CCR-23-1700.

Abstract

Trastuzumab deruxtecan (T-DXd) is reshaping the therapeutic landscape of HER2-positive tumors. A recent article reports on the preclinical activity of the combination of T-DXd plus adavosertib, WEE1 kinase inhibitor, which promises to expand the use of this antibody-drug conjugate in HER2-positive tumors with CCNE1 coamplification. See related article by DiPeri et al., p. 4385.

Publication types

  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / pharmacology
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / genetics
  • Camptothecin / pharmacology
  • Camptothecin / therapeutic use
  • Female
  • Humans
  • Immunoconjugates* / pharmacology
  • Immunoconjugates* / therapeutic use
  • Neoplasms* / drug therapy
  • Neoplasms* / genetics
  • Receptor, ErbB-2 / genetics
  • Trastuzumab / therapeutic use

Substances

  • trastuzumab deruxtecan
  • Antibodies, Monoclonal, Humanized
  • Receptor, ErbB-2
  • Trastuzumab
  • Camptothecin
  • Immunoconjugates